Newsroom

Inquiries

Rory Williams
Director of Communications and Marketing
212-327-8603
[email protected]

Ben Short
Senior Manager of Science Communications and Marketing
212-327-7053
[email protected]
 

Follow us on Bluesky: JCB | JEM | JGP | JHI | RUP

Follow us on X/Twitter: JCB | JEM | JGP| JHI | RUP

Embargoed media alerts and PIO Tip Sheets

Sign up for a weekly preview of articles to be published in Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM),  Journal of General Physiology (JGP), and Journal of Human Immunity (JHI) by contacting Rory Williams. Media alerts are for journalists only. Rockefeller University Press (RUP) also posts PIO Tip Sheets in EurekAlert every Tuesday to notify authors’ institutions of articles that have been accepted for publication in RUP journals.

Latest Press Releases

Intravesical CAR T therapy opens door to bladder-sparing cancer treatment
Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center, and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells. The study, to be published June 26 in the Journal of Experimental Medicine (JEM), demonstrates that direct delivery of these CAR T cells via a catheter can control bladder tumors in mice, raising hopes that a similar approach may be effective in humans. Read more...
June 26, 2026 10:00 AM

Researchers identify new target to prevent aggressive form of prostate cancer
Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease. The study, to be published May 28 in the Journal of Experimental Medicine (JEM), shows that genetic or pharmacological inhibition of Sirtuin 1 prevents the growth of NEPC tumors in mice, and lays the groundwork for future clinical studies aimed at developing new treatments for NEPC in humans. Read more...
May 28, 2026 10:00 AM

Turning up the volume on macrophage-driven immune responses
As part of the body’s first line of defense against foreign invaders, macrophages play an integral role in the innate immune system. However, the ability of macrophages to interpret and respond to diverse danger signals remains incompletely understood. Researchers from the University of Manchester have now found that increases in cell volume reprogram macrophage gene expression and induce inflammation. The findings, to be published May 7 in the Journal of Cell Biology (JCB), add another piece to the ever-expanding puzzle of immune-related inflammatory responses. Read more...
May 7, 2026 10:00 AM

Extra sets of chromosomes make cells more mobile
Researchers at Tulane University School of Medicine have discovered that if animal cells gain an extra set of chromosomes, a condition known as polyploidy, they activate a stress signaling pathway that causes them to become more mobile and capable of engulfing neighboring cells with normal chromosome numbers. The study, to be published April 21 in the Journal of Cell Biology (JCB), could provide new ways to target polyploid cancer cells, which are thought to promote tumor aggressiveness and therapy resistance. Read more...
Apr 21, 2026 10:00 AM

First-in-class dual HIF inhibitors eliminate breast, colorectal, melanoma, and prostate tumors in mice when combined with immunotherapy
Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be “master regulators” of cancer progression. The study, to be published April 2 in the Journal of Experimental Medicine (JEM), shows that these drugs, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice, suggesting that they could eventually be used to treat a broad range of cancers in humans. Read more...
Apr 2, 2026 10:00 AM

Recent media coverage

6/26/2026 — Intravesical CAR T therapy opens door to bladder-sparing cancer treatment — Journal of Experimental Medicine
GEN News, MedicalXpress, BioNewsCentral, The Medical News
RUP Press Release - Article

5/28/2026 — Researchers identify new target to prevent aggressive form of prostate cancer — Journal of Experimental Medicine
Miami Herald, The Sacramento Bee, GEN News, The Medical News, MedicalXpress
RUP Press Release - Article

5/7/2026 — Turning up the volume on macrophage-driven immune responses — Journal of Cell Biology
GEN News, The Medical News, MedicalXpress
RUP Press Release - Article

4/21/2026 — Extra sets of chromosomes make cells more mobile — Journal of Cell Biology
Futurity, eCancer, MedicalXpress, The Medical News, Phys.org
RUP Press Release - Article

4/2/2026 — First-in-class dual HIF inhibitors eliminate breast, colorectal, melanoma, and prostate tumors in mice when combined with immunotherapy — Journal of Experimental Medicine
GEN News, DongA Science, The Medical News, Bioengineer, MedicalXpress
RUP Press Release - Article

3/31/2026 — Reactivation of dormant regulatory T cells alleviates asthma symptoms in mice — Life Science Alliance
Inside Precision Medicine, LabRoots, The Medical News, Bioengineer, MedicalXpress
RUP Press Release - Article

3/27/2026 — Researchers identify new drug target to prevent development of dangerous blood vessel defects in brain — Journal of Experimental Medicine
GEN News, Neuroscience News, The Medical News, MedicalXpress
RUP Press Release - Article 

Embargo policy

Rockefeller University Press (RUP) makes embargoed material available to eligible journalists and public information officers for research articles appearing in its journals: Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM),  Journal of General Physiology (JGP), and Journal of Human Immunity (JHI). Eligible individuals must agree to follow the terms of the RUP embargo policy:

• Stories or reports on research articles may not be published or placed in the public domain until 10:00 a.m. US Eastern Time on the day of publication. Precise embargo dates and times are clearly marked on all advance material.
• Public information officers (PIOs) may not distribute embargoed materials in the public domain before the embargo date. However, embargoed materials may be distributed to the media by public information officers. Such releases must be clearly identified as embargoed and must include the embargo date and time. PIOs are responsible for taking all necessary steps to ensure that the embargo is honored by all third parties.
• All material from RUP journals can be reused without permission for noncommercial purposes, but must be attributed to the appropriate journal and shared expressly under the same restrictions. See our Creative Commons policy for more information.